17/07/2026 European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU Novartis received FDA traditional approval for Fabhalta® for the treatment of primary IgAN European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU (Ref) Boehringer Ingelheim announced that the European Commission had granted marketing authorization for JASCAYD® (nerandomilast; PDE4B inhibitor) for the treatment of adults with idiopathic pulmonary fibr

26/02/2026 GSK’s linerixibat accepted for Priority review by China’s NMPA in patients with PBC Boehringer acquired an exclusive license for a novel oral therapeutics program for immune diseases from Sitryx Argenx announced topline results from Phase 3 trial of VYVGART in Ocular myasthenia gravis Soligenix received a positive opinion from the EMA on its request for orphan drug designation for SGX945 for the treatment of behçet's disease GSK’s linerixibat accepted for Priority